AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's
disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term …

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that effects 50 million
people worldwide. In this review, AD pathology and the development of novel therapeutic …

A novel series of hybrid molecules were designed and synthesized by fusing the
pharmacophoric features of cholinesterase inhibitor donepezil and diarylthiazole as …

Acetylcholinesterase (AChE) is an important enzyme and target for human therapeutics,
environmental safety, and global food supply. Inhibitors of this enzyme are also used for pest …

Alzheimer's disease (AD) is a serious progressive neurological disorder, characterized by
impaired cognition and profound irreversible memory loss. The multifactorial nature of AD …

Alzheimer's Disease (AD), affecting a large population worldwide, is characterized by the old
population's loss of memory and learning ability. Cholinergic deficiency is associated with …

Background: The design of multifunctional agents represents one of the most active
research field in medicinal chemistry. In particular, tacrine, a well known …

Tacrine is a potent inhibitor of cholinesterases (acetylcholinesterase and
butyrylcholinesterase) that shows limiting clinical application by liver toxicity. In spite of this …

Alzheimer's disease (AD) is a progressive neurodegenerative brain disease. Thus, drugs
including donepezil, rivastigmine, and galantamine are not entirely effective in the treatment …